The Fred Hutchinson/University of Washington Cancer Consortium (Consortium) brings together more than 450 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. Over the next grant period, the Consortium will seek to: (1) Continue its leadership in cellular immunotherapy, with the goal of making this therapeutic platform the standard of care for many malignancies; (2) Build on our outstanding strengths in cancer basic biology to increase collaborative translational research, including using genomic and epigenomic technologies to develop effective prognostic tests for solid tumor cancers, applying protein engineering to novel cancer therapeutics, and developing robust mouse models of cancer for rapid screening of drug response prior to therapeutic intervention; (3) Expand our pioneering efforts to reduce the global burden of cancer through translational research on infection-related malignancies, application of global disease surveillance data, and unique international partnerships in Africa (Uganda and South Africa) and more recently China to establish robust platforms for improving our understanding of the spectrum of cancer biology and disease worldwide; (4) Lead research that supports provision of efficient, effective and cost-effective cancer care through research in health economics, cancer outcomes and comparative effectiveness; and (5) Lead population-based research to uncover new insights into the link between obesity and cancer, and to reduce disparities in cancer risk, outcomes and access to care in underserved populations.

Public Health Relevance

There were an estimated 1.6 million new cases of cancer in the United States in 2013, and an estimated 580,000 deaths from the disease. Cancer is the second leading cause of the death in the U.S. The goal of the Fred Hutchinson/University of Washington Cancer Consortium is the elimination of cancer through more effective prevention, diagnosis, and treatment, deriving from fundamental insights into the biology of the disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-41
Application #
9001906
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2019-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
41
Fiscal Year
2016
Total Cost
$9,561,228
Indirect Cost
$3,551,814
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications